BRPI0817045A2 - Tratamento de condições estrogênio-dependentes em mulheres pré-menopáusicas - Google Patents

Tratamento de condições estrogênio-dependentes em mulheres pré-menopáusicas

Info

Publication number
BRPI0817045A2
BRPI0817045A2 BRPI0817045A BRPI0817045A2 BR PI0817045 A2 BRPI0817045 A2 BR PI0817045A2 BR PI0817045 A BRPI0817045 A BR PI0817045A BR PI0817045 A2 BRPI0817045 A2 BR PI0817045A2
Authority
BR
Brazil
Prior art keywords
estrogen
treatment
premenopausal women
dependent conditions
dependent
Prior art date
Application number
Other languages
English (en)
Portuguese (pt)
Inventor
Ernest Loumaye
Jean-Pierre Gotteland
Original Assignee
Preglem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Preglem Sa filed Critical Preglem Sa
Publication of BRPI0817045A2 publication Critical patent/BRPI0817045A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
BRPI0817045 2007-09-17 2008-09-04 Tratamento de condições estrogênio-dependentes em mulheres pré-menopáusicas BRPI0817045A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96010907P 2007-09-17 2007-09-17
PCT/IB2008/002296 WO2009037539A2 (en) 2007-09-17 2008-09-04 Treatment of oestrogen dependant conditions in pre-menopausal women

Publications (1)

Publication Number Publication Date
BRPI0817045A2 true BRPI0817045A2 (pt) 2015-03-24

Family

ID=40468492

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817045 BRPI0817045A2 (pt) 2007-09-17 2008-09-04 Tratamento de condições estrogênio-dependentes em mulheres pré-menopáusicas

Country Status (7)

Country Link
US (1) US20100204146A1 (enExample)
EP (1) EP2207544A2 (enExample)
JP (1) JP5543920B2 (enExample)
KR (1) KR20100068287A (enExample)
BR (1) BRPI0817045A2 (enExample)
CA (1) CA2698814A1 (enExample)
WO (1) WO2009037539A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2647378A1 (en) 2012-04-05 2013-10-09 PregLem S.A. Steroid sulfatase inhibitor regimen for the treatment of endometriosis
EP2647379A1 (en) 2012-04-05 2013-10-09 PregLem S.A. Combined use of a steroid sulfatase inhibitor for the treatment of endometriosis
EP2968367A1 (en) 2013-03-14 2016-01-20 Laboratoire HRA Pharma Method for scheduling ovulation
KR101686986B1 (ko) * 2014-07-28 2016-12-16 에스케이케미칼주식회사 류프로라이드를 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
KR102397510B1 (ko) 2014-12-23 2022-05-13 주식회사 젬백스앤카엘 난소 기능 보존용 펩티드 및 이를 포함하는 조성물
EP3900613B1 (en) 2017-03-31 2023-12-27 Biora Therapeutics, Inc. Localization methods for an ingestible device
CN110809473A (zh) * 2017-06-01 2020-02-18 延世大学校产学协力团 用于预防或治疗骨相关疾病的药物组合物
WO2019110688A1 (en) * 2017-12-05 2019-06-13 Ferring B.V. A composition comprising degarelix for use in the treatment of breast cancer
WO2023150267A1 (en) * 2022-02-03 2023-08-10 Maison Amori Oqvpo Llc Methods, compositions and uses for treating cancer by providing medications that induce targeted tumor cell mitosis before providing chemotherapy or radiation and kits therefor
WO2025219964A1 (en) * 2024-04-19 2025-10-23 J Dental Care Srl Composition for use in the treatment of perimenopausal and post-menopausal symptomatology and in the combined hormonal contraceptive treatment

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
GB9625334D0 (en) 1996-12-05 1997-01-22 Imperial College Compound
GB9603325D0 (en) 1996-02-16 1996-04-17 Imperial College A compound
GB9118478D0 (en) 1991-08-29 1991-10-16 Imperial College Steroid sulphatase inhibitors
GB9118465D0 (en) 1991-08-29 1991-10-16 Imperial College Steroid sulphatase inhibitors
DE69532894T2 (de) * 1994-11-22 2004-09-02 Balance Pharmaceuticals, Inc., Pacific Palisades Verfahren zur empfängnisverhütung
GB9807779D0 (en) 1998-04-09 1998-06-10 Ciba Geigy Ag Organic compounds
JP4320089B2 (ja) * 1999-07-06 2009-08-26 あすか製薬株式会社 フェニルスルファメート誘導体
CO5261573A1 (es) 1999-11-19 2003-03-31 Novartis Ag Derivados de benzoxa y bezotiazol, compuesto y composicion farmaceutica que los contiene y proceso para la preparacion de la mencionada composicion
GB0020498D0 (en) 2000-08-18 2000-10-11 Sterix Ltd Compound
GB0025788D0 (en) 2000-10-20 2000-12-06 Sterix Ltd Use
WO2003006027A1 (en) * 2001-07-13 2003-01-23 Schering Aktiengesellschaft Combination of drospirenone and an estrogen sulphamate for hrt
AR037097A1 (es) 2001-10-05 2004-10-20 Novartis Ag Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
PT1448592E (pt) 2001-10-18 2006-07-31 Sterix Ltd Compostos esteroides para inibicao da esteroide sulfatase
BR0214373A (pt) 2001-11-21 2004-10-13 Sterix Ltd Derivados de 1,2,4-triazol contendo um grupo sulfamato como inibidores de aromatase
PE20040167A1 (es) 2002-03-28 2004-05-26 Novartis Ag Amidas del acido sulfamico
JPWO2004035089A1 (ja) * 2002-10-09 2006-02-09 協和醗酵工業株式会社 ホルモン依存性癌の治療剤
AR041952A1 (es) 2002-11-14 2005-06-01 Novartis Ag N-sulfonilaminotiazol
EP1644350B1 (en) * 2003-05-16 2009-07-01 Laboratoire Theramex Sulfamate benzothiophene derivatives as steroid sulfatase inhibitors
CA2526338C (en) * 2003-05-22 2012-09-25 Pantarhei Bioscience B.V. Use of compositions comprising an estrogenic component for the treatment and prevention of musculoskeletal pain
TW200533668A (en) 2003-12-15 2005-10-16 Theramex 1-n-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them
GB0411562D0 (en) 2004-05-24 2004-06-23 Sterix Ltd Compound
GB0412492D0 (en) 2004-06-04 2004-07-07 Sterix Ltd Compound
GB0505541D0 (en) 2005-03-17 2005-04-27 Novartis Ag Organic compounds
GB0525323D0 (en) 2005-12-13 2006-01-18 Sterix Ltd Compound

Also Published As

Publication number Publication date
KR20100068287A (ko) 2010-06-22
CA2698814A1 (en) 2009-03-26
US20100204146A1 (en) 2010-08-12
WO2009037539A2 (en) 2009-03-26
JP2010539153A (ja) 2010-12-16
JP5543920B2 (ja) 2014-07-09
WO2009037539A3 (en) 2009-07-16
EP2207544A2 (en) 2010-07-21

Similar Documents

Publication Publication Date Title
BRPI0817045A2 (pt) Tratamento de condições estrogênio-dependentes em mulheres pré-menopáusicas
EP2320045A4 (en) APPARATUS FOR TREATING EXHAUST GAS
GB2463797B (en) Skin treating device
BR112012001325A2 (pt) tratamento de distúrbios do fígado com inibidaores de pi3k
BRPI0910259A2 (pt) métodos de tratamento de inflamação
EP2154969A4 (en) TREATMENT OF SYNNUCLEOPATHY
PL2059223T3 (pl) Kompozycja do pielęgnacji skóry
EP2434975A4 (en) PLASMA DEVICE FOR PROCESSING LARGE FABRIC SURFACES
BR112012005594A2 (pt) tratamento de câncer
EP2391208A4 (en) COMPOSITIONS FOR THE TREATMENT OF NAILS AND SKIN
DK2330887T3 (da) Behandlingsindretning
EP2310006A4 (en) CANCER TREATMENT
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BRPI0919150A2 (pt) aplicadores de fluxo de ar e métodos de tratamento relacionados
EP2125002A4 (en) TREATMENT OF SKIN CANCER
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BRPI1007603A2 (pt) "composição de tratamento do cabelo"
EP2465593A4 (en) METHOD OF TREATING WATER AND FLOCCULATING WATER TREATMENT
PL2240018T3 (pl) Kompozycja zawierająca środek przeciwbólowy i przeciwhistaminowy
EP2209458A4 (en) COMPOSITIONS FOR SKIN TREATMENT
GB201107350D0 (en) Topical treatment of skin infection
EP3381471C0 (en) PAIN TREATMENT
HRP20170225T1 (hr) Fosfoplatini i njihova uporaba za liječenje karcinoma
BRPI0812932A2 (pt) Composições e métodos de tratar câncer
PL2187967T3 (pl) Sposoby i kompozycje do leczenia raka

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.